Skip to main content

IgG and Fc Receptor Genetic Variation Associates With Functional Antibody Responses in a DNA and Protein Candidate HIV Vaccine Trial.

Publication ,  Journal Article
Conley, HE; Oh, SY; Garrett, N; Kublin, J; Monaco, CL; Watts, S; Jha, S; Ferrari, G; Tomaras, GD; Geraghty, DE; Chan, C; Pollara, J
Published in: J Acquir Immune Defic Syndr
December 1, 2025

BACKGROUND: The HVTN108 trial evaluated the safety and immunogenicity of a DNA prime, adjuvanted protein boost HIV vaccine in the United States and South Africa. The underlying factors influencing individual variation in vaccine responsiveness are unknown. In this study, we defined the IgG Fc and Fc receptor (FcR) genotypes in the HVTN108 cohort to test our hypothesis that IgG and FcR genetic variation can affect vaccine-elicited functional antibody responses. METHODS: IgG Fc and FcR alleles were determined by targeted PCR amplification and next-generation sequencing. Vaccine-elicited functional antibody responses, including binding antibody multiplex assay (BAMA), antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP) activity, were measured using standardized and qualified methods. Relationships between alleles and antibody responses were identified by linear regression controlling for treatment group and region. RESULTS: The distribution of many polymorphisms significantly differed between the United States and South Africa. Within the subset of the cohort tested for functional antibody responses (IgG, n = 41; FcR, n = 55), IgG genotypes such as IGHG1*12 ( P = 0.012), IGHG3*11 ( P = 0.033), IGHG2*02 ( P = 0.038), IGHG4*07 ( P = 0.076), and others were associated with ADCC antibody responses when corrected for vaccine group and regional effects. In the same way, we identified that the FCER1A rs2427827 mutation had a significant association with lower peak ADCC activity and the FCER2 rs2228137 mutation was associated with lower antibody binding to Con6 gp120 protein. CONCLUSIONS: Genetic variation in both antibodies and FcRs associated with levels of HIV-vaccine-elicited functional antibodies. Significant regional differences in distribution of this variation support the need for vaccine testing in diverse populations.

Duke Scholars

Published In

J Acquir Immune Defic Syndr

DOI

EISSN

1944-7884

Publication Date

December 1, 2025

Volume

100

Issue

4

Start / End Page

371 / 375

Location

United States

Related Subject Headings

  • Virology
  • Vaccines, DNA
  • United States
  • South Africa
  • Receptors, Fc
  • Male
  • Immunoglobulin G
  • Humans
  • HIV Infections
  • HIV Antibodies
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Conley, H. E., Oh, S. Y., Garrett, N., Kublin, J., Monaco, C. L., Watts, S., … Pollara, J. (2025). IgG and Fc Receptor Genetic Variation Associates With Functional Antibody Responses in a DNA and Protein Candidate HIV Vaccine Trial. J Acquir Immune Defic Syndr, 100(4), 371–375. https://doi.org/10.1097/QAI.0000000000003734
Conley, Haleigh E., Song Young Oh, Nigel Garrett, James Kublin, Cynthia L. Monaco, Spencer Watts, Shalini Jha, et al. “IgG and Fc Receptor Genetic Variation Associates With Functional Antibody Responses in a DNA and Protein Candidate HIV Vaccine Trial.J Acquir Immune Defic Syndr 100, no. 4 (December 1, 2025): 371–75. https://doi.org/10.1097/QAI.0000000000003734.
Conley HE, Oh SY, Garrett N, Kublin J, Monaco CL, Watts S, et al. IgG and Fc Receptor Genetic Variation Associates With Functional Antibody Responses in a DNA and Protein Candidate HIV Vaccine Trial. J Acquir Immune Defic Syndr. 2025 Dec 1;100(4):371–5.
Conley, Haleigh E., et al. “IgG and Fc Receptor Genetic Variation Associates With Functional Antibody Responses in a DNA and Protein Candidate HIV Vaccine Trial.J Acquir Immune Defic Syndr, vol. 100, no. 4, Dec. 2025, pp. 371–75. Pubmed, doi:10.1097/QAI.0000000000003734.
Conley HE, Oh SY, Garrett N, Kublin J, Monaco CL, Watts S, Jha S, Ferrari G, Tomaras GD, Geraghty DE, Chan C, Pollara J. IgG and Fc Receptor Genetic Variation Associates With Functional Antibody Responses in a DNA and Protein Candidate HIV Vaccine Trial. J Acquir Immune Defic Syndr. 2025 Dec 1;100(4):371–375.

Published In

J Acquir Immune Defic Syndr

DOI

EISSN

1944-7884

Publication Date

December 1, 2025

Volume

100

Issue

4

Start / End Page

371 / 375

Location

United States

Related Subject Headings

  • Virology
  • Vaccines, DNA
  • United States
  • South Africa
  • Receptors, Fc
  • Male
  • Immunoglobulin G
  • Humans
  • HIV Infections
  • HIV Antibodies